Borui Pharmaceuticals (688166.SH): BGM0504 tablets approved to conduct clinical trials in adult overweight/obese patients.

Zhixun Finance APP, Borui Pharmaceuticals (688166.SH) announced that its wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. ("Borui Pharmaceutical") recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration ("NMPA"), approving Borui Pharmaceutical's BGM0504 tablets to conduct clinical trials in adult overweight/obese patients.